BIOLASE, INC: Nasdaq/NYSE listing notice — BIOLASE receives Nasdaq deficiency notice for bid price below $1.00

BIOLASE, INC

On March 4, 2024, Nasdaq notified BIOLASE that its common stock closing bid price was below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until September 3, 2024, to regain compliance by achieving $1.00 close for at least 10 consecutive business days.
If not cured by Compliance Date, may be eligible for additional 180 days if other listing standards met and a reverse stock split effected.
Company previously received deficiency notices for stockholders' equity and market value, but was granted extension and recently found compliant on Rule 5550(b)(1).
Company intends to monitor bid price and consider available options, including a reverse stock split if necessary.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BIOLASE, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 4, 2024, BIOLASE, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, ending on March 1, 2024, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until S

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-24-058505

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.